Author details

Full Name

Nicholaos C Bellos

Affiliation

ORCID

Career Start Year

2000

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
28272164	Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.	Journal of acquired immune deficiency syndromes (1999)	2017
23134624	ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.	HIV Clinical Trials	2012
21684853	Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.	HIV Clin Trials	2011
20542844	Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.	HIV Clinical Trials	2010
21182345	Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.	Pharmacoeconomics	2010
21051598	The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.	Science	2010
20613461	Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.	AIDS	2010
19542866	Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.	AIDS	2009
18540803	A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.	J Infect Dis	2008
18670229	First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.	AIDS	2008
18091608	Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function.	J Acquir Immune Defic Syndr	2008
18832245	Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.	N Engl J Med	2008
17416261	Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.	Lancet	2007
15747252	T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.	Journal of Infectious Diseases	2005
15238771	SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.	AIDS	2004
15577413	Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation.	J Acquir Immune Defic Syndr	2004
12965939	Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.	Annals of Internal Medicine	2003
14620390	Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.	Pharmacotherapy	2003
12407485	Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients.	HIV Clinical Trials	2002
11797183	Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.	Clinical Infectious Diseases	2002
10983647	A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).	AIDS	2000